Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy sews up £24mln financing deal to bring cancer breakthrough to London

The AIM-listed firm is using technology developed by scientists working on the large hadron collider at the CERN facility in Switzerland to create a low-cost proton beam treatment for cancer.
picture of scientists in the control centre for the large hadron collider.
Scientists working trying to identify the 'God particle' have also helped in the battle against cancer.

Advanced Oncotherapy PLC (LON:AVO) has signed a deal that will allow it provide up to £24mln of vendor financing for the company’s first LIGHT machine in Harley Street, London.

Last October the company announced the formation of the proton beam cancer therapy centre in the capital.

The London Proton Therapy Centre will be funded with £6mln of equity from Advanced Oncotherapy and its partners along with a vendor loan from AVO.

A fund advised by Metric Capital is providing the cash. Shortly following the signing of the deal, £11mln can be drawn down.

The remainder becomes available following the completion of a £25mln cash or capital injection to bankroll the development of a manufacturing base.

AIM-listed AVO is using technology developed by scientists working on the large hadron collider at the CERN facility in Switzerland to create a low-cost proton beam treatment for cancer.

The technology is called LIGHT, which stands for Linac Image Guided Hadron Technology.

Read - What is proton beam therapy?

Cheaper and smaller than the current units, which are almost prohibitively expensive, the LIGHT system has the ability to propel protons at the speeds generated by much larger machines.

Proton beam therapy is expected to emerge as the go-to treatment for tumours as the price of the technology comes down.

It uses the aforementioned protons to pinpoint tumours more precisely.

This limits the damage caused by radiation to surrounding tissue and organs as well as offering patients higher disease-free survival rates.

The piece of the kit that accelerates the protons was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the "God particle".

Chief operating officer Nicolas Serandour said vendor financing of the sort announced today had become an integral component to developing undertakings of this kind.

"We are delighted to have secured this financing partnership with Metric Capital,” he added.

The company’s partners include international companies such as Thales, Toshiba and VDL.

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

September 28 2018

Related Articles

December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use